Safety and Efficacy of Salvage Neck Dissection Following Carbon-ion Radiotherapy with Chemotherapy for a Patient with Mucosal Malignant Melanoma of Head and Neck
Hidenori Suzuki,
Eiichi Sasaki,
Risa Motai,
Seiya Goto,
Daisuke Nishikawa,
Shintaro Beppu,
Hoshino Terada,
Michi Sawabe,
Nobuhiro Hanai
Affiliations
Hidenori Suzuki
Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-0021, Japan
Eiichi Sasaki
Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya 464-0021, Japan
Risa Motai
Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-0021, Japan
Seiya Goto
Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-0021, Japan
Daisuke Nishikawa
Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-0021, Japan
Shintaro Beppu
Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-0021, Japan
Hoshino Terada
Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-0021, Japan
Michi Sawabe
Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-0021, Japan
Nobuhiro Hanai
Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-0021, Japan
Mucosal malignant melanoma of the head and neck is a rare diagnosis. The safety and efficacy of salvage neck dissection following carbon−ion radiotherapy with concurrent chemotherapy are not well described, and carbon−ion radiation protocols have not been fully developed. A 77 year old woman with crT0N1M0 mucosal melanoma of the head and neck achieved a complete response following initial treatment with carbon−ion radiotherapy and concurrent chemotherapy. She was treated with salvage neck dissection for as a cervical lymph node metastasis 16 months after initial treatment. She experienced neither Clavien-Dindo Grade 3 or 4 postoperative complications nor subsequent recurrence of disease at 3 months following salvage neck dissection. Surgical specimens may be useful for future precision oncology based on the molecular biology of recurrence melanoma with poor prognosis.